SkinBioTherapeutics plc (AIM:SBTX)
London · Delayed Price · Currency is GBP · Price in GBX 15.75
-0.10 (-0.63%)
Dec 31, 2025, 11:21 AM GMT+1
SkinBioTherapeutics Revenue
In the fiscal year ending June 30, 2025, SkinBioTherapeutics had annual revenue of 4.64M GBP with 283.74% growth. SkinBioTherapeutics had revenue of 3.06M in the half year ending June 30, 2025, with 5,459.30% growth.
Revenue
4.64M
Revenue Growth
+283.74%
P/S Ratio
8.79
Revenue / Employee
113.13K
Employees
41
Market Cap
40.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 4.64M | 3.43M | 283.74% |
| Jun 30, 2024 | 1.21M | 1.08M | 815.26% |
| Jun 30, 2023 | 132.06K | 57.30K | 76.64% |
| Jun 30, 2022 | 74.76K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| Convatec Group | 1.72B |
| Genus | 672.80M |
| HUTCHMED (China) | 439.54M |